Abstract：
OBJECTIVE: To assess the safety and efficacy of percutaneous cryoablation (CA) of soft-tissue tumors (desmoid tumors (DT), vascular malformations (VM), and abdominal wall endometriosis (AWE)).
METHODS: This systematic review of studies published before January 2024 encompassed a detailed analysis of CA techniques and technical aspects for the treatment of soft-tissue tumors. Data concerning CA efficacy, complication rates, and other relevant metrics was extracted and included for analysis.
RESULTS: The analysis included 27 studies totaling 554 CA procedures. For DT (13 studies, 393 sessions), CA showed an average pain reduction of 79 ± 17% (range: 57-100) and a lesion volume decrease of 71.5 ± 9.8% (range: 44-97). VM (4 studies, 58 sessions) had a 100% technical success rate and an average pain reduction of 72 ± 25% (range: 63-85). The average pain reduction for AWE (6 studies, 103 sessions) was 82 ± 13% (range: 62-100). Overall, the complication rate for CA was low, with minor adverse events (AE) in about 20% of patients and major events in less than 5% of patients.
CONCLUSIONS: Showing substantial efficacy in pain reduction and lesion volume decrease, as well as low incidence of severe AE, CA presents as a highly effective and safe alternative for the treatment of soft-tissue tumors.
CONCLUSIONS: CA is effective and safe in treating soft-tissue tumors, particularly DT, VM, and AWE.
METHODS: This systematic review of studies published before January 2024 encompassed a detailed analysis of CA techniques and technical aspects for the treatment of soft-tissue tumors. Data concerning CA efficacy, complication rates, and other relevant metrics was extracted and included for analysis.
RESULTS: The analysis included 27 studies totaling 554 CA procedures. For DT (13 studies, 393 sessions), CA showed an average pain reduction of 79 ± 17% (range: 57-100) and a lesion volume decrease of 71.5 ± 9.8% (range: 44-97). VM (4 studies, 58 sessions) had a 100% technical success rate and an average pain reduction of 72 ± 25% (range: 63-85). The average pain reduction for AWE (6 studies, 103 sessions) was 82 ± 13% (range: 62-100). Overall, the complication rate for CA was low, with minor adverse events (AE) in about 20% of patients and major events in less than 5% of patients.
CONCLUSIONS: Showing substantial efficacy in pain reduction and lesion volume decrease, as well as low incidence of severe AE, CA presents as a highly effective and safe alternative for the treatment of soft-tissue tumors.
CONCLUSIONS: CA is effective and safe in treating soft-tissue tumors, particularly DT, VM, and AWE.
摘要：
目的：评估经皮冷冻消融（CA）治疗软组织肿瘤的安全性和有效性。血管畸形（VM），腹壁子宫内膜异位症（AWE））。
方法：这项对2024年1月之前发表的研究的系统综述包括对治疗软组织肿瘤的CA技术和技术方面的详细分析。有关CA疗效的数据，并发症发生率,和其他相关指标被提取并纳入分析。
结果：分析包括27项研究，共554项CA程序。对于DT(13项研究，393次会议)，CA显示平均疼痛减少79±17％（范围：57-100），病变体积减少71.5±9.8％（范围：44-97）。VM(4项研究，58次会议）的技术成功率为100％，平均疼痛减轻为72±25％（范围：63-85）。AWE的平均疼痛减轻(6项研究，103个疗程）为82±13%（范围：62-100）。总的来说,CA的并发症发生率低，约20％的患者发生轻微不良事件（AE），不到5％的患者发生主要事件。
结论：显示在疼痛减轻和病变体积减小方面的实质性疗效，以及严重AE的低发病率，CA是治疗软组织肿瘤的高效和安全的替代方案。
结论：CA治疗软组织肿瘤是有效和安全的，尤其是DT,VM,AWE。
方法：这项对2024年1月之前发表的研究的系统综述包括对治疗软组织肿瘤的CA技术和技术方面的详细分析。有关CA疗效的数据，并发症发生率,和其他相关指标被提取并纳入分析。
结果：分析包括27项研究，共554项CA程序。对于DT(13项研究，393次会议)，CA显示平均疼痛减少79±17％（范围：57-100），病变体积减少71.5±9.8％（范围：44-97）。VM(4项研究，58次会议）的技术成功率为100％，平均疼痛减轻为72±25％（范围：63-85）。AWE的平均疼痛减轻(6项研究，103个疗程）为82±13%（范围：62-100）。总的来说,CA的并发症发生率低，约20％的患者发生轻微不良事件（AE），不到5％的患者发生主要事件。
结论：显示在疼痛减轻和病变体积减小方面的实质性疗效，以及严重AE的低发病率，CA是治疗软组织肿瘤的高效和安全的替代方案。
结论：CA治疗软组织肿瘤是有效和安全的，尤其是DT,VM,AWE。
